FDA: Black Box Warning Label Decision Pending on Avandia Diabetes Drug
An announcement on the decision of whether to add a second black-box warning
to the label of Avandia is pending, said the U.S. Food and Drug Administration
(FDA) on November 14, 2007.
An agency advisory panel voted in June to
keep the Type 2 diabetes drug on the market but opted also to include new
warnings highlighting the increased heart attack risk.
The drug already
carries a black box warning for heart failure. The new one for heart attack
would indicate that it is less safe than its competitors, which don't carry that
warning.
If you or a loved one has suffered cardiac complications after
ingesting Avandia, you deserve the guidance of a knowledgeable drug attorney.
Get a free case review by filling out the form below.
see also:
Avandia Panel, 7.25.07
Academic Panel of Scientists to Meet With FDA Regarding Avandia RisksScientific Panel to Advise FDA on Avandia Heart Attack Risk
Firm's Press Release, 10.1.07
Weitz & Luxenberg Lawyers Respond to Study Casting Doubt on AvandiaW&L Lawyers React to Growing Scientific Evidence Against Avandia
News & Warnings
Avandia Breaking News: Glaxo Warned in 2001 about Misleading MarketingBloomberg News: FDA Warned Glaxo about Avandia Marketing in 2001


